My Cart [ 0 ]
Home > Cell Biology > Stable Cell Lines > Remicade Biosimilar Stable Cell Line

Remicade Biosimilar Stable Cell Line

Infliximab, Anti-TNF alpha Chimeric Monoclonal Antibody

Catalog No. Product Name Size List Price (US$) Quantity
C011 Remicade Biosimilar Stable Cell Line 1 package Request

Infliximab (trade name Remicade, Janssen Biotech), a chimeric anti-TNF-α monoclonal antibody, is used to treat psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab interferes TNF-α from binding to its receptor in the cell.

Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNFα) plays important roles in the regulation of autoimmune reaction.

C011: Remicade Biosimilar Stable Cell Line (CHO)

The yield of Remicade biosimilar from the CHO stable cell line was above 1.5 g/L in flask.

The Remicade biosimilar stable cell line alone can be transfered alone or together with the technology of process development and/or antibody purification.

Syd Labs also provides the following anti-TNF antibody biosimilar stable cell line:
Humira Biosimilar Stable Cell Line

Related Links

See our Privacy Policy